Skip to main content
. Author manuscript; available in PMC: 2025 Jan 6.
Published in final edited form as: Int J Drug Policy. 2019 Aug 20;74:26–32. doi: 10.1016/j.drugpo.2019.07.038

Table 1:

Study sample demographics (N = 40).

Characteristics N %
Gender, female 11 28%
Race/Ethnicity White 25 63%
African American 6 15%
Hispanic 8 20%
Biracial, multiracial or other 1 3%
Age, mean (SD, range, IQR) 43 (11.5, 21-60, 34-52)
HIV status, positive 4 10%
HCV status, positive 33 83%
Ever homeless 39 98%
Ever enrolled in drug treatment 35 88%
Ever injected opioids 40 100%
Personal ODs, lifetime, mean (SD, range, IQR) 6.4 (15.9, 1-100, 1-4)
Number ODs prior 12 months Zero 19 48%
One 14 35%
≥Two 7 18%
Witnessed ODs, lifetime, mean (SD, range, IQR) 14.6 (22.6, 1-100, 3.5-14)
Number witnessed overdoses, prior 12 months Zero 11 28%
1-5 22 55%
≥6 7 18%
Years of illicit opioid use, lifetime, mean (SD, range, IQR) 24.5 (11.7, 4-52, 17-33.5)